[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
May 17, 2016

Utility of Cancer Value Frameworks for Patients, Payers, and Physicians

Author Affiliations
  • 1Harvard University, Cambridge, Massachusetts
  • 2Precision Health Economics, Los Angeles, California
  • 3Merck, Kenilworth, New Jersey
JAMA. 2016;315(19):2069-2070. doi:10.1001/jama.2016.4915

In recent years, novel cancer therapies have improved the expected survival of patients but have also increased treatment costs. As a result of these increases, patients are concerned about increasing out-of-pocket costs, clinicians must assess whether “do no harm” includes patient financial harm, and payers want to know if novel therapies are worth the cost.1

To answer these questions, some organizations have created value frameworks that can be applied to cancer therapies. The American Society of Clinical Oncology (ASCO),2 European Society for Medical Oncology (ESMO),3 Institute for Clinical and Economic Review (ICER),4 Memorial Sloan Kettering Cancer Center (MSKCC),5 and National Comprehensive Cancer Network (NCCN)6 have all developed value frameworks. These organizations define value conceptually as a measure of treatment benefits relative to cost, but each organization uses a different method for measuring value. This Viewpoint describes the methodological differences across these frameworks and provides recommendations for improving them for clinicians, patients, and payers.

First Page Preview View Large
First page PDF preview
First page PDF preview
×